This article is more than 5 years old. Information may no longer be current.
Study: IL-23 inhibitor more effective than Stelara in treating psoriasis
Click Here to Manage Email Alerts
SAN FRANCISCO — In this video, Kim Papp, MD, PhD, discusses the late-breaking research he presented at the American Academy of Dermatology Annual Meeting on a phase 2 study of a novel interleukin-23 inhibitor compared with Stelara in patients with moderate-to-severe plaque psoriasis.
Papp and colleagues found BI 655066 (Boehringer Ingelheim), a selective interleukin (IL)-23p19 antagonist monoclonal antibody, was more effective than Stelara (ustekinumab, Janssen) in achieving Psoriasis Area Severity Index 90 score at week 12, the study’s primary endpoint.
The researchers found superiority of BI 655066 in the 90-mg and 180-mg treatment cohorts when compared with the ustekinumab treatment, which was administered according to the approved label. Comparable rates of response were found between the 18-mg dosing arm of BI 655066 and ustekinumab at week 12, Papp said.